Department of Otolaryngology-Head and Neck Surgery, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, MSC 7800, San Antonio, TX 78229-3900, USA.
J Vasc Interv Radiol. 2010 Aug;21(8):1271-9. doi: 10.1016/j.jvir.2010.02.027. Epub 2010 May 15.
Minimally invasive interventional cancer therapy with drug-carrying lipid nanoparticles (ie, liposomes) via convection-enhanced delivery by an infusion pump can increase intratumoral drug concentration and retention while facilitating broad distribution throughout solid tumors. The authors investigated the utility of liposome-carrying beta-emitting radionuclides to treat head and neck cancer by direct intratumoral infusion in nude rats.
Four groups of nude rats were subcutaneously inoculated with human tongue cancer cells. After tumors reached an average size of 1.6 cm(3), the treatment group received an intratumoral infusion of liposomal rhenium-186 ((186)Re) (185 MBq [5 mCi]/cm(3) tumor). Three control groups were intratumorally infused with unlabeled liposomes, unencapsulated (186)Re-perrhenate, or unencapsulated intermediate (186)Re compound ((186)Re-N,N-bis[2-mercaptoethyl]-N',N'-diethyl-ethylenediamine [BMEDA]). In vivo distribution of (186)Re activity was measured by planar gamma-camera imaging. Tumor therapy and toxicity were assessed by tumor size, body weight, and hematology.
Average tumor volume in the (186)Re-liposome group on posttreatment day 14 decreased to 87.7% +/- 20.1%, whereas tumor volumes increased to 395.0%-514.4% on average in the other three groups (P< .001 vs (186)Re-liposome). The (186)Re-liposomes provided much higher intratumoral retention of (186)Re activity, resulting in an average tumor radiation absorbed dose of 526.3 Gy +/- 93.3, whereas (186)Re-perrhenate and (186)Re-BMEDA groups had only 3.3 Gy +/- 1.2 and 13.4 Gy +/- 9.2 tumor doses, respectively. No systemic toxicity was observed.
Liposomal (186)Re effectively treated head and neck cancer with minimal side effects after convection-enhanced interventional delivery. These results suggest the potential of liposomal (186)Re for clinical application in interventional therapy of cancer.
通过输注泵进行的对流增强式传递,利用载药脂质纳米颗粒(即脂质体)进行微创介入癌症治疗,可以增加肿瘤内的药物浓度和滞留时间,同时促进实体肿瘤的广泛分布。作者通过裸鼠的直接肿瘤内输注,研究了载有β发射放射性核素的脂质体用于治疗头颈部癌症的效用。
四组裸鼠皮下接种人舌癌细胞。当肿瘤平均大小达到 1.6cm³时,治疗组接受肿瘤内输注载铼-186(186Re)的脂质体(185MBq [5mCi]/cm³肿瘤)。三组对照组分别接受未标记的脂质体、未包裹的(186)Re-高铼酸盐或未包裹的中间(186)Re 化合物(186Re-N,N-双[2-巯基乙基]-N',N'-二乙基乙二胺[BMEDA])的肿瘤内输注。通过平面伽马相机成像测量(186)Re 活性的体内分布。通过肿瘤大小、体重和血液学评估肿瘤治疗和毒性。
治疗后第 14 天,(186)Re-脂质体组的平均肿瘤体积下降至 87.7%±20.1%,而其他三组的肿瘤体积平均增加至 395.0%-514.4%(P<.001 与(186)Re-脂质体相比)。(186)Re 脂质体提供了更高的肿瘤内(186)Re 活性保留,导致平均肿瘤吸收剂量为 526.3Gy±93.3,而(186)Re-高铼酸盐和(186)Re-BMEDA 组的肿瘤剂量分别为 3.3Gy±1.2 和 13.4Gy±9.2。未观察到全身毒性。
脂质体(186)Re 通过对流增强式介入传递有效地治疗头颈部癌症,副作用极小。这些结果表明,脂质体(186)Re 具有在癌症介入治疗中临床应用的潜力。